New drug combo targets Tough-to-Treat leukemia
NCT ID NCT02737046
Summary
This study tested whether adding the drug belinostat to standard zidovudine (AZT) therapy could help control adult T-cell leukemia-lymphoma (ATLL), a rare and aggressive blood cancer. Fifteen adults with ATLL received the combination treatment to see if it could eliminate cancer cells from the blood and bone marrow. Researchers measured how many participants achieved a deep response, how long they stayed disease-free, and monitored side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.